SELLAS Life Sciences Group Inc sell Bankster
Start price
03.08.26
/
50%
€9.74
Target price
-
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w |
|---|---|
| SELLAS Life Sciences Group Inc | - |
| iShares Core DAX® | 2.334% |
| iShares Nasdaq 100 | 1.370% |
| iShares Nikkei 225® | 2.437% |
| iShares S&P 500 | 1.259% |
Comments by Bankster for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Sell SELLAS Life Sciences Group Inc